Titlebook: Dose-Finding Designs for Early-Phase Cancer Clinical Trials; A Brief Guidebook to Takashi Daimon,Akihiro Hirakawa,Shigeyuki Matsui Book 201

別炫耀

Atheroma

Early-Phase Cancer Clinical Trials,administered to a cancer patient, so as to obtain the highest efficacy while maintaining admissible toxicity. Thus, in oncology, early-phase trials for anticancer agents are also called “dose-finding” trials. For a chemotherapeutic or cytotoxic agent, classically, the OD is determined in the phase I

gene-therapy

ARC

Model-Based Designs Considering Toxicity Alone, trials can be classified as rule-/algorithm- or model-based designs. In Chap. ., we focused on rule-based designs; in the present chapter, we focus on model-based designs. Model-based designs assume a certain statistical model for the monotonic dose–toxicity relationship to borrow strength across d

evasive

Occlusion

侵略

–LOUS

Ringworm

食品室

Mathematics and Its Applicationsmay not hold for molecularly targeted or cytostatic agents, or for immunotherapeutic agents (IAs). The ODs of such agents are found in phase I/II trials, in which both toxicity and efficacy are evaluated to determine the dose that yields the highest efficacy and admissible toxicity, or the dose that